A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with
recurrent or progressive glioblastoma after prior antiangiogenic therapy (including anti-VEGF
therapy)
Phase:
Phase 2
Details
Lead Sponsor:
Tracon Pharmaceuticals Inc.
Collaborators:
Case Comprehensive Cancer Center The Cleveland Clinic